• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, April 10, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

An asymptomatic patient with severe mitral regurgitation

Bioengineer by Bioengineer
April 18, 2018
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In the current issue of Cardiovascular Innovations and Applications (Volume 2, Number 4, 2018, pp 431-434(4); DOI: https://doi.org/10.15212/CVIA.2017.0034, researcher Blase A. Carabello, from East Carolina University, Greenville, NC, USA presents a case study of an asymptomatic patient with severe mitral regurgitation.

In primary mitral regurgitation there are anatomic abnormalities of the mitral valve causing backward flow, placing a hemodynamic burden on the left ventricle. If this burden is severe and prolonged, it leads to left ventricular damage, heart failure, and death. The preferred therapy is restoration of mitral competence through mitral valve repair, which is safer than mitral valve replacement. When repair is performed in a timely fashion, lifespan can be returned to that of a normal individual. Triggers for timely repair include the onset of symptoms and evidence of left ventricular dysfunction as determined by ejection fraction falling toward 60% and/or end-systolic dimension increasing toward 40 mm.

When symptoms or early LV dysfunction occur in patients with primary MR, mitral valve repair or replacement must be performed to avoid irreversible LV dysfunction, heart failure, and death. However, primary nonrheumatic MR is usually treated in experienced hands with mitral valve repair instead of replacement, avoiding the complications of prosthetic heart valves. When there is 95% confidence that a durable repair can be effected, early surgery becomes an important option instead of waiting for symptoms or LV dysfunction to occur, sparing the patient from frequent follow-up examinations and/or the possibility that one of these triggers for surgery will be missed, subjecting the patient to a poor outcome.

###

Media Contact

Morgan Lyons
[email protected]

Home

http://dx.doi.org/10.15212/CVIA.2017.0034

Share12Tweet7Share2ShareShareShare1

Related Posts

MESH1 Controls Sulfation by Acting as PAPS Phosphatase

April 10, 2026

Chiral Gold Nanohelices Target Arthritis via Spin Control

April 10, 2026

iNOS Regulates Inflammation via IRG1 in Mitochondria

April 10, 2026

Neural Circuits Driving Directed Turning in C. elegans

April 10, 2026
Please login to join discussion

POPULAR NEWS

  • Boosting Breast Cancer Risk Prediction with Genetics

    47 shares
    Share 19 Tweet 12
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1012 shares
    Share 400 Tweet 250
  • Revolutionary Theory Transforms Quantum Perspective on the Big Bang

    41 shares
    Share 16 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

MESH1 Controls Sulfation by Acting as PAPS Phosphatase

Chiral Gold Nanohelices Target Arthritis via Spin Control

Machine Learning Reveals Arctic Land Albedo Feedbacks

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.